Marqibo: Clinical Trials

12 trials of Marqibo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 terminated, 1 recruiting, 1 withdrawn. 12 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 8, Terminated 2, Recruiting 1, Withdrawn 1
Phase 15Completed 4, Withdrawn 1

Follow Marqibo: new trials by email Literature Review of Marqibo trials Research Report on Marqibo

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Phase 1 / Phase 2WithdrawnRoswell Park Cancer Institute2021-01-212022-01-28
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Bortezomib, Clofarabine, Cyclophosphamide - Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma
Phase 2RecruitingM.D. Anderson Cancer Center422017-08-092026-08-10
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Lenalidomide, Rituximab, Prednisone - Primary Effusion Lymphoma, B-Cell Neoplasm
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)172017-07-032026-11-12
Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Vincristine Sulfate Liposome, Laboratory Biomarker Analysis - Recurrent Adult Acute Myeloid Leukemia
Phase 2TerminatedWake Forest University Health Sciences52015-06-052019-08-14
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Rituximab, Imatinib, Cyclophosphamide - Leukemia
Phase 2CompletedM.D. Anderson Cancer Center312013-03-052022-09-27
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Cixutumumab, Cyclophosphamide, Dactinomycin - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Phase 2CompletedNational Cancer Institute (NCI)1752010-01-012017-08-29
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
cyclophosphamide, cytarabine, dexamethasone - Leukemia
Phase 2TerminatedOHSU Knight Cancer Institute112009-06-012023-01-06
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Phase 2CompletedNational Cancer Institute (NCI)1482009-03-012017-01-27
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - Recurrent Childhood Acute Lymphoblastic Leukemia
Phase 1 / Phase 2CompletedChildren's Oncology Group1342005-02-012017-12-12
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Vincristine Sulfate Liposomes Injection, Dexamethasone - Acute Lymphoblastic Leukemia
Phase 1 / Phase 2CompletedAcrotech Biopharma Inc.362002-07-012019-12-12
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Vincristine Sulfate Liposome Injection plus rituximab - Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2CompletedAcrotech Biopharma Inc.222001-09-012020-01-03
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)3481993-05-082025-06-22

Conditions studied

Precursor Cell Lymphoblastic Leukemia-Lymphoma (5)  ·  Burkitt Lymphoma (3)  ·  Leukemia (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, AIDS-Related (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, Primary Effusion (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Rhabdomyosarcoma (1)  ·  Sarcoma (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  Acrotech Biopharma Inc. (2)  ·  M.D. Anderson Cancer Center (2)  ·  Children's Oncology Group (1)  ·  OHSU Knight Cancer Institute (1)  ·  Roswell Park Cancer Institute (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (12)  ·  Australia (3)  ·  Canada (3)  ·  Puerto Rico (2)  ·  New Zealand (1)  ·  United Kingdom (1)

Top investigators

Brandon Hayes-Lattin (1)  ·  Deborah Thomas, MD (1)  ·  Elias Jabbour, MD (1)  ·  Elizabeth Raetz, MD (1)  ·  Eunice S Wang (1)  ·  Gareth Morgan, Prof. (1)  ·  Lawrence Kaplan, MD (1)  ·  Leonard Heffner, MD (1)  ·  Mark J Roschewski, M.D. (1)  ·  Maro Ohanian (1)  ·  Ramya Ramaswami, MBBS, MPH (1)  ·  Suman Malempati, MD (1)  ·  Terzah Horton, MD PhD (1)  ·  Timothy Pardee (1)  ·  Wendy Stock, MD (1)

Results publications

PMID 23574119, PMID 24224624, PMID 25024303, PMID 28419486, PMID 29748435, PMID 30125215, PMID 30957229, PMID 34432874, PMID 35882475

NIH funding

U10CA098543 (3), U10CA180886 (2), P30CA012197 (1)